Johnson & Johnson (NYSE:JNJ) announced today that it agreed to acquire Abiomed (Nasdaq:ABMD) for approximately $16.6 billion. Under the agreement, Johnson & Johnson intends to acquire through tender offer all outstanding Abiomed shares. That amounts to an upfront payment of $380 per share in cash. Johnson & Johson plans to complete the transaction before the […]
Johnson & Johnson
5 top trends shaping the medtech industry
Ashley McEvoy is an industry veteran and the EVP and worldwide chair of Johnson & Johnson MedTech. Michael Minogue, another veteran, serves as chair, president and CEO of heart pump maker Abiomed. Together, the two bring a wealth of medtech industry knowledge to the table. They demonstrated that in a “CEOs Unplugged” discussion at AdvaMed’s […]
How Johnson & Johnson is looking to lead the way in ablation
Celine Martin, Johnson & Johnson group chair, cardiovascular & specialty solutions (CSS) group, oversees high-growth areas at the company’s global MedTech business. Her leadership covers Acclarent, Biosense Webster, Cerenovus and Mentor. Together, those companies bring in more than $5 billion in annual sales with more than 14,000 employees. Over 25 years at Johnson & Johnson, […]
What does the future hold for AI in medical devices?
Digital health, artificial intelligence (AI), machine learning and more — these concepts continue to generate buzz in the medtech world. Last month, the FDA published guidance on clinical decision support (CDS) software. It helped to clear up what constitutes a medical device and what doesn’t. Early last year, the agency published a predetermined change control […]
Johnson & Johnson beats The Street in Q3, MedTech sales rise
Johnson & Johnson (NYSE:JNJ) today reported third-quarter results that topped the consensus forecast, with MedTech business sales up more than 2%. The New Brunswick, New Jersey-based company posted profits of $4.5 billion, or $1.68 per share in the quarter. It pulled in sales of $23.8 billion for the three months ended Sept. 30, 2022. That […]
Biosense Webster launches HelioStar in Europe
Biosense Webster today launched its HelioStar balloon ablation catheter in Europe. Johnson & Johnson’s subsidiary Biosense Webster launched the radiofrequency balloon ablation catheter for catheter-based cardiac electrophysiological mapping of the atria when used with a multi-channel RF generator. According to the company, more than 11 million people in Europe have AFib. The expectation is that […]
Johnson & Johnson Vision launches overnight, intraocular lenses
Johnson & Johnson Vision announced today that it launched an expanded range of Acuvue Abiliti overnight lenses, as well as a new intraocular lens. The FDA approved an expanded range of the Acuvue Abiliti overnight therapeutic lenses for myopia (nearsightedness) management. The approval covers lenses up to six diopters, widening the range from the previously approved […]
5 top ophthalmic device innovations you need to know
Innovation finds its way into all areas of medtech, and ophthalmic treatments represent another burgeoning space. It may not be a new wave, but medtech companies continue to improve upon technologies for the human eye. Implants, lenses and more comprise the space’s latest innovations, with a number of companies finding new ways to fix old […]
Report: J&J Vision spending €100 million to expand Irish facility
J&J Vision reportedly plans to invest €100m in the expansion of its Plassey, Limerick, Ireland facility. The Irish Examiner reported last week that the company plans to expand and create 80 new jobs at the location. In March, the company announced a €35 million investment in the same facility. That cash infusion aimed to create […]
J&J announces $5B share repurchase
Johnson & Johnson (NYSE: JNJ) announced today that its board has authorized a $5 billion repurchase of its common stock. “The last few years have demonstrated the resilience of Johnson & Johnson. With continued confidence in our business and pipeline, the board of directors and management team believe that company shares are an attractive investment […]
J&J settles big Australian pelvic mesh case
Johnson & Johnson (NYSE: JNJ) has settled an Australian pelvic mesh class action suit for AU$300 million (roughly U.S. $205 million), according to media reports. Shine Lawyers, which handled the suit, confirmed the settlement. It still requires court approval. More than 11,000 claimants in Australia had sought relief, according to Reuters. In a statement shared […]
